GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Phase 2/3 Recruiting 80 enrolled Xiaojun Chen

RandomizedParallel-groupOpen-labelTreatment

Summary

To investigate the efficacy of GnRHa plus letrozole vs Diane-35 plus metformin in non-obese progestin-insensitive early-stage endometrial cancer (EEC) and atypical hyperplasia(EAH) patients asking for conservative treatment.

Timeline

Start: 2022-07-13
Primary completion: 2026-03-30
Completion: 2027-03-30

Publications

Background Zhou S, Xu Z, Yang B, Guan J, Shan W, Shi Y, Chen X. Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment. J Gynecol Oncol. 2021 Jul;32(4):e57. doi: 10.3802/jgo.2021.32.e57.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Diane-35	Unknown	—	Oral
Subject	Letrozole	Other / unclassified	2.5 mg	Oral
Subject	Leuprolide	Other / unclassified	3.75 mg	Intramuscular
Subject	MET	Unknown	500 mg	Oral

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Summary

Timeline

Publications

Drugs

Indications